FILTER

Refine your search with the following facets to narrow down your results.

21 Current news of PolyTherics

PolyTherics’ growth spurs move to larger premises

25-Aug-2010 - PolyTherics Limited announced it has moved to larger premises to accommodate a growing team of scientists developing biobetters and novel proteins and peptides, both in-house and in partnership with pharmaceutical and biotechnology companies. Since its establishment in 2002, PolyTherics has ...

biotechnology peptides proteins

PolyTherics appoints new Chairman

18-Jun-2010 - PolyTherics Limited announced that Dr Ken Cunningham has been appointed Chairman. Dr Mike Hayes, the current Non-Executive Chairman, will continue as a Non-Executive Director. Dr Cunningham has over 20 years’ experience in the pharmaceutical industry. He is currently Chief Executive Officer ...

PolyTherics Initiates New Research and Option Agreement with Top Ten Pharmaceutical Company

29-Apr-2010 - PolyTherics Limited announced a research and option agreement with one of the world’s top ten pharmaceutical companies. PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to its collaborator. The study will utilise PolyTherics’ ...

antibody fragments biologics PEGylation +1

PolyTherics receives a Technology Strategy Board grant to develop novel fusion proteins

16-Apr-2010 - PolyTherics Limited announced that it has started work on a Technology Strategy Board (“TSB”) funded project to produce fusion proteins using its chemical linker technologies. PolyTherics will chemically fuse different but complementary proteins using its proprietary polyethylene glycol (PEG) ...

fusion proteins PEGylation proteases +1

Zealand Pharma and PolyTherics enter Collaboration Agreement for novel optimised biopharmaceuticals

03-Mar-2010 - Zealand Pharma and PolyTherics Limited announced a research collaboration. Zealand has developed a number of peptide-based therapeutic candidates which are amenable to PEGylation. PolyTherics has broad capabilities in improving the duration of action of biotherapeutics using targeted PEGylation ...

biologics gastrointestinal diseases PEGylation +2

PolyTherics Raises £3 million to Commercialise PEGylationTechnologies

19-Feb-2010 - PolyTherics Limited announced the completion of an investment round of £3.0 million in the company. The investment round was led by Imperial Innovations Group plc, the technology investment and commercialisation company, and included Longbow Capital and The Capital Fund. This investment follows ...

biologics PEGylation peptides +1

Celtic Pharma Holdings and PolyTherics announce investment into novel biopharmaceutical programme

28-Jan-2010 - Celtic Pharma Holdings Advisors LLP, the advisor to Celtic Pharma Holdings II LP (“CP2”), together with PolyTherics Limited announced an investment into a research programme to develop a novel biopharmaceutical molecule. This research programme will be undertaken jointly by PolyTherics and ...

biopharmaceuticals drug development PEGylation +2

PolyTherics and Minapharm Pharmaceuticals Sign Collaboration Agreement to Create Enhanced Biopharmaceuticals

15-Sep-2009 - PolyTherics Limited announced the initiation of a research collaboration agreement with Minapharm Pharmaceuticals. PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to Minapharm. Minapharm has an option to license the collaboration ...

biopharmaceuticals collaborations PEGylation +2

PolyTherics Receives Second Patent Allowance in Record Time

07-Jul-2009 - PolyTherics Limited announced that a second patent has been allowed covering the targeted PEGylation of proteins. Issued by the United States Patent Office, this allowance protects PolyTherics’ PEGylation technology in the two largest pharmaceutical markets in the world. This news comes two weeks ...

antibody fragments dosing Expression +3

PolyTherics TheraPEGTM Patent Allowed in Europe

23-Jun-2009 - PolyTherics Limited announced that its first patent covering the targeted PEGylation of proteins has been allowed in Europe. The patent claims the use of a unique linker developed at PolyTherics that enables precision attachment of PEG to natural disulfide bonds in proteins. Trademarked as ...

antibody fragments dosing Expression +4